With Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer

An opportunity for decentralized sequencing attracted Foresite to lead GenapSys' $90M series C

GenapSys has netted a $90 million series C led by Foresite Capital to introduce a genetic sequencer that is designed to deliver high-accuracy results at low cost without the need for a central laboratory.

GenapSys Inc.'s shoebox-sized sequencer costs $10,000 and uses sensors on chips to measure the electrical signature

Read the full 498 word article

User Sign In